Genecast PARPguide is our proprietary multi-gene mutation detection kit, utilizing capture-based targeted DNA NGS to provide a comprehensive genomic profiling approach to guide PARP inhibitor therapies. It is intended for qualitative detection of genomic HRD status and mutations in 66 homologous recombination repair (‘HRR’)-related genes in DNA samples. Genecast PARPguide is indicated for patients with breast cancer, ovarian cancer, prostate cancer or pancreatic cancer.

Genecast PARPguide comprises two testing modules, namely HRR Gene Mutation Assay and HRD Status Testing. The HRR Gene Mutation Assay comprehensively predicts PARP inhibitor efficacy by analyzing 66 homologous HRR pathway genes including BRCA1/BRCA2, detecting point mutations, indels, copy number losses in specified genes, and large genomic rearrangements (‘LGR’) in BRCA1/2. The HRD Status Testing evaluates genomic instability through three biomarkers: Loss of Heterozygosity, Telomeric Allelic Imbalance, and Large-Scale State Transitions to determine HRD status with high precision. This is achieved through a proprietary algorithm that combines a SNP panel with shallow whole-genome sequencing, offering promising accuracy and sensitivity, particularly for samples with low tumor content.

Designed for use in breast, ovarian, prostate, and pancreatic cancers, Genecast PARPguide not only broadens genomic coverage beyond BRCA1/2 by including the entire HRR pathway but also enables detection of BRCA LGRs, which may account for over 10% of BRCA deficiencies. Together, these features make Genecast PARPguide a powerful tool for identifying patients likely to benefit from PARP inhibitors.

We obtained CE marking for Genecast PARPguide for PARP inhibitor therapy selection in ovarian cancer, breast cancer, prostate cancer and pancreatic cancer.